Radiolabeled Antibodies for Cancer Imaging and Therapy
journal contributionposted on 18.05.2022, 05:33 authored by Sagun ParakhSagun Parakh, Sze LeeSze Lee, Hui GanHui Gan, Andrew ScottAndrew Scott
Radioimmunoconjugates consist of a monoclonal antibody (mAb) linked to a radionuclide. Radioimmunoconjugates as theranostics tools have been in development with success, particularly in hematological malignancies, leading to approval by the US Food and Drug Administration (FDA) for the treatment of non-Hodgkin’s lymphoma. Radioimmunotherapy (RIT) allows for reduced toxicity compared to conventional radiation therapy and enhances the efficacy of mAbs. In addition, using radiolabeled mAbs with imaging methods provides critical information on the pharmacokinetics and pharmacodynamics of therapeutic agents with direct relevance to the optimization of the dose and dosing schedule, real-time antigen quantitation, antigen heterogeneity, and dynamic antigen changes. All of these parameters are critical in predicting treatment responses and identifying patients who are most likely to benefit from treatment. Historically, RITs have been less effective in solid tumors; however, several strategies are being investigated to improve their therapeutic index, including targeting patients with minimal disease burden; using pre-targeting strategies, newer radionuclides, and improved labeling techniques; and using combined modalities and locoregional application. This review provides an overview of the radiolabeled intact antibodies currently in clinical use and those in development.
S.P is the recipient of a Fellowship from the Victorian Government Department of Health and Human Services acting through the Victorian Cancer Agency. A.M.S is the recipient of an NHRMC Investigator Fellowship No. 1177837.
Article NumberARTN 1454
Rights Statement© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Read the peer-reviewed publication
Science & TechnologyLife Sciences & BiomedicineOncologyradioimmunotherapyradioisotopesradiolabeled monoclonal antibodiestheranosticsPHASE-I TRIALY-90 IBRITUMOMAB TIUXETANNON-HODGKINS-LYMPHOMACARBONIC-ANHYDRASE IXCARCINOEMBRYONIC ANTIGEN RADIOIMMUNOTHERAPYANTI-CD22 FRACTIONATED RADIOIMMUNOTHERAPYHEMATOPOIETIC-CELL TRANSPLANTATIONCOLORECTAL LIVER METASTASESHER2-POSITIVE BREAST-CANCERMURINE MONOCLONAL-ANTIBODY